DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Understanding Molecular Mechanisms of Secondary Resistance in Patients with Metastatic Castrate Resistant Prostate Cancer
[Technical Report, Annual Report]
SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK
Pagination or Media Count:
One of the fundamental ways to slow down the progression of prostate cancer in men is to reduce the action of androgens, suchas testosterone, on prostate cancer tissue. Certain drugs directly reduce androgen levels, while others, such as bicalutamideCasodex, prevent androgen action on its receptor. However, even with these androgendeprivation therapies, a proportionof cancers escape and progressthis phenomenon is termed primary resistance. To counteract this resistance, a secondgeneration of antiandrogen therapies, namely enzalutamide Xtandi, apalutamide Erleada, darolutamide Nubeqa andabiraterone Zytiga has emerged over the last decade. While each drug effectively overcomes primary resistance, all tumorsfinally escape and progress. Such secondary resistance currently poses a major clinical challenge, as patients rapidly follow adownhill course.
[A, Approved For Public Release]